Uncategorized

Protected: The curious case of Axsome Therapeutics

This content is password protected. To view it please enter your password below: Password:

Jerome VeronyJanuary 3, 2020

AcademiaBiotechFinance

Refractory Status Epilepticus: Significant new insights and a potential paradigm shift

Artwork by Greg A. Dunn After what you could call a professionally-induced hiatus, I am…

Jerome VeronyDecember 4, 2019

ArtsTravel

Summer Solstice in Barcelona

Below are a few impressions from Barcelona and Badalona around the 2019 'Sant Joan' celebrations…

Jerome VeronyJune 24, 2019

Biotech

Initial clinical data suggests KRAS inhibition provides benefit to cancer patients

Wars are won one battle at a time If you follow the cancer space closely,…

Jerome VeronyMay 16, 2019

AcademiaBiotech

Nav1.7: a tough nut to crack

  A recently published piece in the journal nature reviews: drug discovery outlines the challenges involved with…

Jerome VeronyApril 11, 2019

Academia

Challenging the dogma of statistical significance in the interest of better decision-making

Statistical inference is the perilous but necessary exercise of drawing conclusions from (sometimes very) limited…

Jerome VeronyApril 1, 2019

Arts

Book review: ‘La Photographe’

As a student at Paris' SciencesPo, I would occastionally bemoan the seeming absence of, or…

Jerome VeronyMarch 19, 2019

Biotech

Intercept’s NASH fibrosis breakthrough and perceptions around commercial viability

Intercept Pharmaceuticals, which develops & commercializes obeticholid acid ('OCA') in several indications, has reported positive…

Jerome VeronyMarch 6, 2019

AcademiaBiotech

New findings show LRRK2 may play crucial role in a significant portion of Parkinson’s disease (‘PD’) patients

A small enzyme known as LRRK2 - named after the genes that encode it - appears to…

Jerome VeronyJuly 26, 2018